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A role for hypercholesterolemia in the development
of osteoporosis has been suggested in published re-
ports. However, few studies contain direct evidence of
a role for maintenance of cholesterol homeostasis in
bone health. Using isocaloric high-fat/high-choles-
terol and low-fat/no-cholesterol diets in a 4-month
feeding study combined with micro computed tomog-
raphy analysis, we demonstrated in two different
mouse strains that mice with hypercholesterolemia
lose cortical and trabecular bone in the femurs and
vertebrae (bone mineral density was decreased on
average by 90 mg/mL in the cortical vertebrae in
one strain) and cortical bone in the calvariae (bone
mineral density was decreased on average by 60
mg/mL in one strain). Mechanical testing of the
femurs demonstrated that loss of bone in the mice
with hypercholesterolemia caused changes in the
mechanical properties of the bone including loss of
failure load (failure load was decreased by 10 N in
one strain) and energy to failure. Serologic and
histomorphologic analyses suggested that hyper-
cholesterolemia promotes osteoclastogenesis. These
studies support a role for hypercholesterolemia in
the development of osteoporosis and provide a
model with which to test intervention strategies to
reduce the effects of hypercholesterolemia on bone
health. (Am J Pathol 2012, 181:928–936; http://dx.doi.org/
10.1016/j.ajpath.2012.05.034)
Osteoporosis is the most common bone disorder, and is
characterized by systemic reduction in bone mass and
928changes in the bone microarchitecture that result in fra-
gility fractures.1 The increased risk of spontaneous and
traumatic bone fractures can lead to disability, often se-
vere and permanent; placement in institutional care; and
death. Osteoporotic fractures of the hip and spine result
in mortality of up to 20% for 1 year after the fracture
event.2
Recent evidence links the risk of developing osteopo-
rosis to both cardiovascular disease and metabolic syn-
drome3–10 (defined as central obesity with insulin resis-
tance, and/or dyslipidemia and high blood pressure),
which suggests that a common element between these
conditions may also be operating to increase the risk of
osteoporosis. Although not always present in individuals
with cardiovascular disease or metabolic syndrome, hy-
percholesterolemia is a common factor in those with ei-
ther disease.
Osteoblasts (cells that make bone) and osteoclasts
(cells that resorb bone) synthesize cholesterol endoge-
nously via the mevalonate pathway and absorb choles-
terol-containing lipoproteins from the circulation. Conse-
quently, control of cellular cholesterol content is a
balance between metabolic processes intrinsic to the cell
and the regulation of cholesterol distribution by the or-
ganism. Maintenance of the overall cholesterol content of
cell membranes is determined by a complex set of pro-
cesses including synthetic pathways in the endoplasmic
reticulum, regulation of lipogenic genes by cholesterol-
regulated sterol-response element binding proteins, re-
ceptor-mediated internalization, intracellular transport
mechanisms, and cholesterol efflux via lipoprotein com-
plexes.11–13 Despite the elaborate mechanisms for main-
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teoclasts, like other cells, are subject to disruptions in
cholesterol homeostasis as a consequence of dysregu-
lation in endogenous synthetic pathways, poor choles-
terol efflux, and/or systemic changes in serum cholesterol
concentrations. These changes may result in altered cel-
lular responses to specific growth factors and/or cyto-
kines, as well as changes in the ability of bone cells to
mature, differentiate, and stabilize bone.
Epidemiologic evidence indicates elevated serum
cholesterol concentration as a risk factor in development
of osteoporosis.5,6,14–21 Other studies have demon-
strated that statin drugs, which inhibit the rate-limiting
step in cholesterol synthesis,22–24 increase bone mineral
density (BMD) in humans, lower fracture risk, and cause
changes in bone cell (osteoblast) biochemistry in vivo and
in tissue culture.25–39 When provided in typical dosages
in humans, statins work almost exclusively in the liver,
where they suppress cholesterol synthesis, leading to
reduced serum cholesterol concentrations. Simply
stated, the level of extrahepatic statin is too small and for
too short a time for the purported direct extrahepatic
tissue effects of statins to occur.22–24,40–50 Consequently,
if statins alter risk of developing osteoporosis, this phe-
nomenon likely stems from their effects on circulating
cholesterol concentrations, and not from direct effects on
osteoblasts and osteoclasts.
Because of the suggested links between cardiovascu-
lar disease, metabolic syndrome, and osteoporosis,3–10
previous studies that have suggested an effect of ele-
vated cholesterol concentration and statins on BMD and
fracture risk,5,6,14–21,25–39 and our understanding of the
roles of cholesterol in bone cell biology, we hypothesized
that altering the level of cholesterol in membranes of
osteoblasts and/or osteoclasts, as a consequence of el-
evated serum cholesterol concentrations, will contribute
to development of osteoporosis.
In a previous study, an atherogenic diet (high-fat/
high-cholesterol [HFHC] with sodium cholate) fed to
mice led to significantly reduced femoral mineral con-
tent (43% lower) and mineral density (15% lower) when
compared with a low-fat/no-cholesterol (LFNC) diet fed
to control animals.51 A more recent study showed that
rats fed a HFHC diet also demonstrated loss of femoral
BMD when compared with rats fed normal chow.52
Neither of these studies used isocaloric diets, and,
therefore, did not rule out energy effects, resulting in
inconclusive interpretation of a specific role for choles-
terol in reducing BMD.
The objective of the present study was to test the
effect of hypercholesterolemia on bone integrity. Using
a novel diet scheme that included isocaloric diets lack-
ing sodium cholate, we demonstrated that hypercho-
lesterolemia is associated with alterations in BMD,
bone volume fraction (BVF; bone volume/total volume),
number of trabeculae, trabecular spacing, and other
physical measures, accompanied by changes in the
mechanical properties of the bone and an increase in
bone resident osteoclasts.Materials and Methods
Mice and Diets
All animal experiments were approved by the Institutional
Animal Care and Use Committee of Children’s Hospital
Boston (protocol A07-06-084). Five-week-old male
C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME)
and C.B-17/Icr-SCID/Sed-Prkdcscid mice (Massachu-
setts General Hospital, Boston, MA) were fed an LFNC
diet (catalog No. D12102; Research Diets, Inc., New
Brunswick, NJ) for 2 weeks, after which blood was drawn
from the saphenous tail vein, and the serum cholesterol
concentration was determined using the Infinity Choles-
terol Liquid Stable Reagent (Thermo Electron Corp., Wal-
tham, MA). The mice were then divided into groups that
received either the HFHC diet (catalog No. D12108; Re-
search Diets) or the LFNC diet for 4 months. Although
these diets differ in composition, they are used isocalo-
rically, ie, by feeding mice the same number of calories in
each diet. Terminal blood samples were obtained via
cardiac puncture for serologic assay (pyridinoline cross-
links assay; Quidel Corp., San Diego, CA) and osteocal-
cin assay (Biomedical Technologies, Inc., Stoughton,
MA). Assays were performed according to the manufac-
turers’ instructions. Triglyceride, insulin, and bilirubin
concentrations, and other liver function tests were per-
formed at the Yale University Mouse Phenotyping Center
(New Haven, CT), and androgen level tests were per-
formed at the Hormone Assay Core, Vanderbilt University
(Nashville, TN).
Histomorphologic Analyses
Femurs were fixed in 10% neutral buffered formalin and
decalcified for 2 weeks at 4°C using 10% EDTA (pH 7.4).
The bones were dehydrated in graded ethanol (50%, 70%,
90%, and 95%) and twice in 100% ethanol for 1 hour each,
cleared twice in xylene for 1 hour each, and embedded in
paraffin. Five-micrometer sections were cut, deparaffinized,
and stained using the TRAP kit (Acid Phosphatase, Leuko-
cyte kit; Sigma Corp., St. Louis, MO) according to the man-
ufacturer’s instructions, and were counterstained with he-
matoxylin. TRAP-stained cells with three nuclei or more
were counted as osteoclasts for quantification.
Bones, Micro Computed Tomography, and
Mechanical Testing
The calvaria, right femurs, and L4 vertebrae were re-
moved immediately after the animals were euthanized,
and were washed in lactated Ringer’s solution. All spec-
imens were scanned and then reconstructed onto 18-m
voxels using a cone beam micro-computed tomography
(microCT) system (GE Healthcare BioSciences Corp.,
Piscataway, NJ) to assess geometric and morphologic
properties. A single threshold was applied to the three-
dimensional dataset, as determined from evaluation of
the calibrated density histograms. Cortical mineralization
and geometric analyses were performed over a 3-mm
mid-diaphyseal segment in the femurs, and trabecular
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bone segmented using a spline algorithm, starting at the
distal growth plate and moving proximally to 20% of the
total femur length. The elements of the spline were inter-
polated to generate a three-dimensional region of inter-
est. Data from each femur were averaged over the entire
region of interest to provide representative values for the
entire three-dimensional mid-diaphysis. Outcome mea-
sures included cross-sectional area, cortical thickness, and
bending moment of inertia. In addition to the femoral prop-
erties, two standardized volumes of trabecular bone were
segmented from the proximal and distal ends of vertebral
bodies. Volumes were determined by identifying the largest
volume of trabecular bone possible by digitizing each sec-
tion to define a series of splines that interpolated the volume
of interest. The trabecular bone in both the femoral metaph-
yses and the vertebrae were evaluated to determine BVF,
trabecular thickness, degree of anisotropy, number of tra-
beculae, and trabecular spacing. The analyses were per-
formed using the advanced analysis programs and
MicroView software suites in the GE MicroCT systems (GE
Healthcare Biosciences). Morphologic analyses of the cal-
variae were performed on segments created using a region
of interest growing tool. All of the algorithms have been
validated in the Orthopaedic Research Laboratories at the
University of Michigan (Ann Arbor).
Biomechanical Properties
Before biomechanical testing, all specimens were main-
tained frozen at 20°C. Testing was performed at room
temperature, and the specimens were maintained moist
using Ringer’s solution. Whole-bone mechanical proper-
ties of the femurs to failure were performed in four-point
bending using a servohydraulic testing machine (858
Mini Bionix II; MTS Systems Corp., Eden Prairie, MN) at a
constant displacement rate of 0.5 mm/second. Femors
were loaded in the anteroposterior direction so that the
posterior side of the bone was in tension and the anterior
side was in compression. All four loading points were
placed in contact with the bone by adjusting the height of
the upper two points independently. Regions loaded in
four-point bending corresponded to those measured us-
ing microCT. Displacement was monitored using a linear
variable differential transducer (Lucas Schaevitz 050
MHR; Measurement Specialties, Inc., Hampton, VA), and
load data were collected using a load cell (Sensotec,
Inc., Columbus, OH) in series with the actuator. Load and
displacement data were sampled at 2000 Hz using the
TestStar IIs system (version 2.4; MTS Systems). Load-
displacement curves were then analyzed for whole-bone
yield load, ultimate load, stiffness, failure energy, and
displacement ratio (ultimate displacement:yield displace-
ment) using MATLAB software (version 6.5; The Math-
Works, Inc., Natick, MA). The predicted tissue modules
and yield strength were calculated using standard me-
chanics of materials equations and geometric properties
calculated during microCT analysis. These equations
predict inherent material properties of the extracellular
matrix, assuming a bending mode of failure.Statistical Analysis
Statistical significance was determined using Student’s
t-test. P  .05 was considered significant.
Results
To understand how hypercholesterolemia affects various
measures related to bone quality, we used two cohorts of
mice fed isocaloric HFHC and LFNC diets, respectively,
for 4 months. Previous testing of these diets indicated
that to raise cholesterol concentrations in mice, a diet
required both additional fat and cholesterol, ie, HFHC
diet,53 whereas the LFNC diet is well-defined and is com-
posed essentially of normal mouse chow. Cohorts of mice
fed these diets did not differ by weight even after 4
months (mean  SD, 37.66  3.68 g LFNC versus
38.61  5.30 g HFHC for C57BL/6 mice, and 31.5  2.93
g LFNC versus 31.31  2.95 g HFHC for SCID mice)
(Figure 1A; see also Supplemental Table S1 at http://ajp.
amjpathol.org), but demonstrated significant differences
in serum cholesterol concentrations (122.23  22.53
Figure 1. Effects of diet on weight and blood chemistry. Mice (14 to 16 per
group) fed an isocaloric high-fat/high-cholesterol diet (black bars) or a
low-fat/no-cholesterol diet (white bars) for 4 months were weighed (A), and
serum cholesterol (B), triglyceride (C), and testosterone (D) concentrations
were determined. A: Body mass. Data are plotted as mean  SD versus diet
group. There is no statistically significant difference between the 2 groups in
either strain. B–D: Serologic measures. Mice were bled via cardiac puncture,
and the serum was subjected to various tests. B: Serum cholesterol concen-
tration was measured in the collected serum via Infinity colorimetric assay.
Data are plotted as mean  SD cholesterol concentration versus group. C:
Triglyceride concentration was measured as described in Materials and
Methods. Data are plotted as triglyceride concentration versus group. D:
Testosterone concentration was measured as described in Materials and Meth-
ods. Data are plotted as mean SE testosterone concentration versus diet group.
In all cases, the Student’s t-test was used to calculate significance. Data were
considered significant at P  0.05. *P  0.05, **P  0.01, and ***P  0.005.
and ***P
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C57BL/6 mice, and 158.11  22.76 mg/dL LFNC versus
181.53  24.82 mg/dL HFHC for SCID mice) (Figure 1B;
see also Supplemental Table S1 at http://ajp.amjpathol.
org). Mice fed the HFHC diet had hypercholesterolemia,
whereas the other group had normal cholesterol concen-
trations. The HFHC diet did raise triglyceride concentra-
tions significantly in SCID mice, but not in C57BL/6 mice
(Figure 1C). Liver toxicity, as determined by liver function
test results, was never detected, and insulin levels were
not significantly different between the diet cohorts, al-
though they trended higher in the C57BL/6 HFHC diet
cohort (data not shown). There were no significant differ-
ences in androgen levels (Figure 1D).
To determine whether elevated serum cholesterol con-
centrations affected bone health, the calvariae, femors,
and vertebral bodies of the mice were removed, cleaned,
and subjected to microCT.
The hypercholesterolemic mice demonstrated signifi-
cant changes in their femors when compared with mice
fed a normocholesterolemic diet, ie, significantly reduced
tissue mineral density (TMD) in the cortical bone regions
(1163.5  20.4 mg/mL LFNC versus 1147.5  16.1
mg/mL HFHC) in the C57BL/6 mice, which also trended
similarly but did not reach statistical significance in the
SCID mice (1273.0 25.7 mg/mL LFNC versus 1249.8
36.9 mg/mL HFHC), and significantly thinner diaphyseal
cortical bone with a smaller cortical surface area in both
strains (Figure 2, A–C; see also Supplemental Table S1 at
http://ajp.amjpathol.org). We also measured significant
differences in the moment of inertia (Iyy) and BMD in
LFNC versus HFHC diet cohorts of C57BL/6 mice (0.27
0.03 mm4 LFNC versus 0.21  0.04 mm4 HFHC) (Figure
Figure 2. Effects of diet on femor
diet (black bars) or a low-fat/no-
removed, cleaned, and analyzed u
(B), cortical surface area (CSA)(C
mean SD versus group. In all case
at P  0.05. *P  0.05, **P  0.01,
Figure 3. Effects of diet on fem
cholesterol diet (black bars) or a lo
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volume/total volume (BV/TV)] (A
trabecular thickness (D), and tissue
the Student’s t-test was used to ca
0.01, and ***P  0.005.2, D and E; see also Supplemental Table S1 at http://
ajp.amjpathol.org). These values trended similarly be-
tween the diets in the SCID mice, but did not reach
statistical significance. The trabecular bone in the femors
of the hypercholesterolemic cohorts also demonstrated
statistically significant changes as compared with normo-
cholesterolemic mice, with a smaller BVF (0.43  0.06
LFNC versus 0.27  0.05 HFHC for the C57BL/6 mice,
and 0.46  0.10 LFNC versus 0.37  0.08 HFHC for the
SCID mice), larger trabecular spacing (0.10  0.02 mm
LFNC versus 0.16  0.03 mm HFHC for the C57BL/6
mice, and 0.09  0.02 mm LFNC versus 0.12  0.07 mm
HFHC for the SCID mice), fewer trabeculae in both strains
(5.59  0.42 LFNC versus 4.51  0.49 HFHC for the
C57BL/6 mice, and 6.21  0.53 LFNC versus 5.53  1.0
HFHC for the SCID mice) (Figure 3, A–C; see also Sup-
plemental Table S1 at http://ajp.amjpathol.org), and sig-
nificantly less trabecular thickness and TMD in the LFNC
diet cohort (691.05  25.43 mg/mL) versus the HFHC
diet cohort (717.37  15.16 mg/mL) of the C57BL/6
strain. These values trended similarly in the SCID mice
(Figure 3, D and E; see also Supplemental Table S1 at
http://ajp.amjpathol.org).
Calvariae from mice fed the HFHC diet versus those
fed the LFNC diet demonstrated significant reductions in
BMD (763.5  55.12 mg/mL LFNC versus 700.98 
45.53 mg/mL HFHC in the C57BL/6 mice, and 713.16 
69.13 mg/mL LFNC versus 664.5  42.6 mg/mL HFHC in
the SCID mice) and mean thickness in both strains
(0.21  0.02 mm LFNC versus 0.20  0.02 mm HFHC in
the C57BL/6 mice, and 0.33  0.05 mm LFNC versus
0.29  0.04 mm HFHC in the SCID mice) (Figure 4,A and
B; see also Supplemental Table S1 at http://ajp.
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the LFNC diet also had significantly higher TMD (826.6 
18.21 mg/mL versus 802.44  17.65 mg/mL), bone min-
eral content (1.08  0.13 mg versus 0.97  0.11 mg),
and tissue mineral content (0.98  0.09 mg versus
0.82 0.09 mg) when compared with mice fed the HFHC
diet, and these measures also trended similarly in the
SCID mouse cohort (Figure 4, C–E; see also Supplemen-
tal Table S1 at http://ajp.amjpathol.org).
The trabecular bone of the vertebral bodies from the
C57BL/6 and SCID HFHC cohorts demonstrated signifi-
cantly fewer trabeculae (7.71 0.19 LFNC versus 7.21
0.46 HFHC for the C57BL/6 mice, and 6.90  0.78 LFNC
versus 5.96  0.79 HFHC for the SCID mice) and larger
trabecular spacing (0.05 0.01 mm LFNC versus 0.08
0.01 mm HFHC for the C57BL/6 mice, and 0.09  0.02
mm LFNC versus 0.11  0.03 mm HFHC for the SCID
mice) than in the LFNC cohorts (Figure 5,A and B; see
also Supplemental Table S1 at http://ajp.amjpathol.org).
In addition, there were also significant differences be-
tween the C57BL/6 HFHC diet mice and LFNC diet mice
in both trabecular thickness (0.08  0.01 mm LFNC ver-
sus 0.06  0.01 mm HFHC) and BVF (0.61  0.05 LFNC
versus 0.45  0.06 HFHC) (Figure 5, C and D; see also
Supplemental Table S1 at http://ajp.amjpathol.org).
In contrast to the overall similarity of the effects of diet
on the C57BL/6 and SCID mice, the effects of diet on
cortical vertebral bone varied between the two strains. In
the C57BL/6 strain, bone mineral content (0.52  0.08
mg LFNC versus 0.45 0.07 mg HFHC), BMD (479.62
25.59 mg/mL LFNC versus 389.53  41.74 mg/mL
HFHC), TMC (0.42  0.07 mg LFNC versus 0.31  0.06
mg HFHC), and TMD (621.43  17.22 mg/mL LFNC
versus 597.03  19.46 mg/mL HFHC) were all signifi-
cantly reduced, whereas in the SCID mice, there were
Figure 4. Effects of diet on the c
(black bars) or a low-fat/no-chol
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(B), tissue mineral density (TMD) (
given as mean  SD versus grou
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Figure 5. Effects of diet on the trabecular bone of vertebrae. Mice (14 t
low-fat/no-cholesterol diet (white bars) for 4 months were sacrificed, and L4 w
of trabeculae (A), trabecular spacing distance between trabeculae (B), trab
(BV/TV)] (D). Data are given as mean  SD versus group. In all cases, the Student
at P  0.05. *P  0.05, ***P  0.005.no significant differences in any of these measure-
ments between the LFNC and HFHC groups, although
bone mineral content, BMD, and TMC measurements
all trended similarly to those of the C57BL/6 strain
(Figure 6, A–D; see also Supplemental Table S1 at
http://ajp.amjpathol.org).
Because the HFHC versus LFNC diet was associated
with significant changes in both mineral content and mi-
croarchitecture of the femors, we next determined
whether these changes resulted in alterations in the me-
chanical properties of the bone (Figure 7; see also Sup-
plemental Table S1 at http://ajp.amjpathol.org). The
femors from the C57BL/6 HFHC cohort were less stiff
(323.08  35.36 N/mm LFNC versus 244.0  42.43
N/mm HFHC), had significantly smaller ultimate and fail-
ure loads (38.41  5.71 N LFNC versus 27.94  4.24 N
HFHC), and less energy to failure (4.28  1.96 N/mm
LFNC versus 2.76  1.29 N/mm HFHC) than did the
femors from the C57BL/6 LFNC group. The mechanical
properties of the femors did not differ in the SCID HFHC
group when compared with the SCID LFNC group (Figure
7, A–D; see also Supplemental Table S1 at http://ajp.
amjpathol.org).
Serologic testing indicated that there were no differ-
ences in osteocalcin levels between the hypercholester-
olemic HFHC cohort and the normocholesterolemic
LFNC cohort, which suggested that altered osteoblast
activity was unlikely to explain the observed changes in
the bone (data not shown). However, we did observe
differences in the level of pyridinoline cross-links found in
collagen I fragments, a measure of osteoclast activity
(Figure 8A). This suggested that increased osteoclast
activity contributes to the osteopenic phenotype of the
hypercholesterolemic mice. Consistent with an effect of
the HFHC diet on osteoclastogenesis, histomorphometric
. Mice (14 to 16 per group) fed an isocaloric high-fat/high-cholesterol diet
diet (white bars) for 4 months were sacrificed, and their calvariae were
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osteoclasts present in the bones of the hypercholester-
olemic versus the normocholesterolemic groups (Figure
8, B and C).
Discussion
In the present study, we demonstrated that diet-induced
hypercholesterolemia in mice is associated with a reduc-
tion in bone quality measures that resemble the bone
quality in humans with osteoporosis.
We concluded that there is likely a direct influence of
hypercholesterolemia on bone health due to the follow-
ing: i) mice were fed isocaloric diets, and, thus, there is
no effect of additional calories in this model, even though
the diets differed in their levels of fat and cholesterol;
ii) the mice did not gain weight with the HFHC diet versus
the LFNC diet, and, thus, any changes that occurred in
bone are not reflective of differences in animal weight
(Figure 1A); iii) multiple parameters of bone quality were
altered by diet, and, thus, the changes detected are likely
to originate in a systematic loss of bone homeostasis and
are not due to an isolated event (Figures 2 to 6);
iv) femors, calvariae, and vertebrae were all affected,
indicating that the source of altered bone quality is sys-
temic (Figures 2 to 6); v) the C57BL/6 HFHC cohort ex-
hibited reduced mechanical properties (Figure 7); and vi)
diet did not influence androgen levels (Figure 1D).
Mice received the HFHC or LFNC diets for 4 months,
which is approximately 16% to 25% of their lifespan. This
should be sufficient time to affect cortical and trabecular
bone, should either diet have any effect.
Testing of the femors of the C57BL/6 mice demon-
strated significant loss of their mechanical properties,
including substantial decreases in stiffness, failure load,
ultimate load, and energy to failure in the HFHC cohort,
Figure 6. Effects of diet on the cortical bone of the vertebrae. Mice (14
low-fat/no-cholesterol diet (white bars) for 4 months were sacrificed, and L4
mineral content (BMC) (A), bone mineral density (BMD) (B), tissue mineral
SD versus group. In all cases, the Student’s t-test was used to calculate sign
Figure 7. Mechanical properties of femors. Mice (14 to 16 per group) fed an
(white bars) for 4 months were sacrificed, and their femors were removed, c
the femors to failure were performed in 4-point bending using a servohydrau
load, ultimate load, stiffness, failure energy, and displacement ratio (ultimate
difference between “start” (centroid coordinate position) and “end” positions was used to
are given as mean  SD. In all cases, the Student’s t-test was used to calculate significawhich suggests that the loss of bone mineral and thinning
of the trabeculae were substantial enough to significantly
weaken the bone. The loss of both physical and mechan-
ical properties implies a resemblance to osteoporosis in
humans. The similarities to osteoporosis in humans in-
clude thinning of the diaphyseal cortical bone, reduced
BVF, thinning trabeculae, loss of trabeculae, increased
osteoclast numbers, and reductions in failure load and
energy to failure. Given the loss of femoral stiffness,
which is likely a reflection of the thinner bone, it is ex-
pected that the bones would be somewhat less brittle;
rather, we found that the bones were more brittle. Thus,
the loss of energy to failure induced by the HFHC diet
likely reflects a change in the material properties of the
bone.
Although in many respects the physical properties
noted in the C57BL/6 mice fed the HFHC versus the
LFNC diet were also present in the SCID mice, for the
most part, they were less pronounced, and most me-
chanical measures were not affected by diet in the SCID
strain.
Although not all of the factors that contribute to native
BMD are known, a combination of environmental and
genetic factors is most probably involved. The effect of
serum cholesterol concentrations on development of an
osteoporotic phenotype is likely, to some degree, also
dependent on native BMD (ie, the BMD before choles-
terol manipulation). On the basis of previous analy-
ses,54–56 and our own data (Figure 2E) for the native
femoral BMD of these strains, C57BL/6 mice have a lower
BMD than does the SCID strain, which shares a back-
ground with Balb/C mice. This result suggests that the
native BMD may influence the degree to which hypercho-
lesterolemia affects bone. A study by Ishimori et al57
suggested that the differential effect of atherogenic diets
in C57BL/6 and 129 strains, which displayed different
r group) fed an isocaloric high-fat/high-cholesterol diet (black bars) or a
oved, cleaned, and analyzed using MicroCT. Measurements included bone
(TMC) (C), and tissue mineral density (TMD) (D). Data are given as mean 
. Data were considered significant at P  0.05. *P  0.05, ***P  0.005.
ric high-fat/high-cholesterol diet (black bars) or a low-fat/no-cholesterol diet
and analyzed via mechanical testing. Whole-bone mechanical properties of
g machine. Load-displacement curves were then analyzed for whole-bone yield
ment:yield displacement), and other measures using MATLAB software. Theto 16 pe
was remisocalo
leaned,
lic testin
displacecalculate stiffness (A), ultimate load (B), failure load (C), and energy (D). Data
nce. Data were considered significant at P  0.05. *P  0.05, ***P  0.005.
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diet, are linked to four quantitative trait loci: Bmd9,
Bmd20, Bmd21, and Bmd22, which collectively ac-
counted for 21.6% of total BMD and 17.3% of vertebral
BMD of the F2 population variances. It is likely that ge-
netic variations, which influence BMD, may have a role in
the effect of diet on the development of osteopenia
in mice.
Another potential reason for the disparate response
between C57BL/6 and SCID mice is that SCID mice are
profoundly immunodeficient owing to the inability of these
mice to perform VDJ recombination, rendering them with-
out functional T and B cells. Although certain inflamma-
tory responses from natural killer cells and macrophages
remain, most inflammation is impaired in these animals.
In a separate study (accepted for publication, PLOS
One), we measured particular inflammatory responses in
the animals as related to diet, and found that the HFHC
diet did contribute to inflammation in the C57BL/6 mice,
which was absent in the SCID mice, consistent with the
known effects of hypercholesterolemia on inflammation.
Proinflammatory cytokines have a role in osteoclasto-
genesis and bone resorption, and are increased during
menopause, which suggests that inflammation and os-
teoporosis are linked.58 Our results are consistent with a
role for inflammation in response to hypercholesterolemia
as a mediator of bone loss, but also suggest that nonin-
flammatory pathways likely mediate some of the effect of
diet on development of osteoporosis because the SCID
mice did lose bone.
Our data (Figure 8) indicate that hypercholesterolemia
increases the number and activity of osteoclasts within
bone. Although increased osteoclast activity could ex-
plain the reduced BMD in both strains, it is notable that
statistically significant effects of hypercholesterolemia
were observed only for serum pyridinoline concentration
(a measure of osteoclast activity) in SCID mice, whereas
more extensive effects of diet on bone were evident in
C57BL/6 mice. This is likely a reflection of the timing of
the assay, which was necessarily performed as an ex-
perimental end point (ie, after 4 months on the diet) at
which the loss of bone in C57BL/6 mice had already
peaked.
Our data suggest that hypercholesterolemia promotes
Figure 8. Bone loss in mice with hypercholesterolemia is linked to increased
diet (black bars) or a low-fat/no-cholesterol diet (white bars) for 4 months w
determined via enzyme-linked immunosorbent assay (A), the femors were
mean SD PYD concentration versus group (n 8 or 9 mice per group). B:
Leukocyte (TRAP) kit, and the total number of osteoclasts in 5 20 fields we
7 bones per group). In all cases, the Student’s t-test was used to calculate sign
demonstrate osteoclasts (arrows) in trabecular regions of the femors in C5
quantification at40 magnification. Left:Most panels are enlargements of origin
staining (light pink) and multiple nuclei (purple). *P  0.05.osteoclastogenesis, consistent with unpublished obser-vations from our laboratory that increasing the exogenous
cholesterol available to macrophages increases the num-
ber and size of the polykaryon (data not shown). It is
possible that hypercholesterolemia affects the mem-
brane composition of both osteoblasts and osteoclasts,
which we hypothesized would in turn affect their ability to
respond to environmental cues. We have published59,60
and unpublished evidence that altering membrane cho-
lesterol levels in osteoblasts affects their responses to
growth factors, but we have no evidence that this is
occurring in vivo.
A number of studies have suggested that high serum
cholesterol concentrations, per se, are associated with
low BMD and osteoporosis in humans.5,14–21 For exam-
ple, Broulik and Kapitola14 measured higher cholesterol
concentrations in patients with osteoporosis with and
without vertebral fractures, respectively, compared with
age-matched patients without osteoporosis. Poli et al21
reported that women with plasma low-density lipoprotein
(LDL) cholesterol concentrations 160 mg/dL had a
more than twofold probability of having osteopenia than
did women with lower LDL cholesterol concentrations
(47.9% versus 21.2%, respectively). Of note, some stud-
ies have not found an association between high choles-
terol concentration (or LDL concentration) and osteopo-
rosis.61,62 For example, Samelson et al,61 using data from
the Framingham Study, examined the relationship be-
tween BMD (femoral head) and total cholesterol concen-
tration, but found no correlation between high cholesterol
concentrations and osteoporosis. Of importance, this
study did not use vertebral measures, LDL cholesterol
concentrations were unknown, and, perhaps most criti-
cal, the subjects were enrolled in 1948, yet their BMD was
not measured until 1988–1989,61 thereby effectively
skewing the data in favor of the null hypothesis because
many subjects with high cholesterol concentrations and
low BMD were likely deceased by 1989. Assessing the
complex relationships between diet, cholesterol concen-
trations, and osteoporosis in a human population is prob-
lematic because all important variables cannot be con-
trolled and data are difficult to obtain.
In the present study, we created a hypercholester-
olemic animal model with which we can determine how
hypercholesterolemia affects bone health. By controlling
lastic activity and osteoclasts. Mice fed an isocaloric high-fat/high-cholesterol
ificed, and serum pyridinoline (PYD) concentration in the murine blood was
at histology, and the osteoclasts were counted (B). A: Data are plotted as
rometer sections of femors were cut and stained using the Acid Phosphatase,
ted. Data are given as mean  SD number of osteoclasts versus group (n 
. Data were considered significant at P 0.05. C: Histomorphometric images
ice. These are representative images of the 20 fields used in the osteoclast
ages demonstrating osteoclasts used for quantification with characteristic TRAPosteoc
ere sacr
analyzed
Five-mic
re coun
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7BL/6 mcalories, animal weight, and other variables, we were
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olemia in mice. It is noteworthy that a previous analysis of
diet and bone in mice determined that an atherogenic
diet that raised cholesterol concentrations was correlated
with loss of BMD. The diet we used in our study also
raised serum cholesterol concentrations significantly, but
was not atherogenic. Mice do not naturally develop ath-
erosclerotic lesions in the aorta similar to those found in
humans.63 An atherogenic diet in mice requires the ad-
dition of sodium cholate, a bile acid.63 Sodium cholate is
not required to raise cholesterol concentrations, but does
cause liver toxicity. Thus, hypercholesterolemic non-
atherogenic diets, such as those used in the present
study, are preferred when determining the relationship
between hypercholesterolemia and disease.
Although the type of analysis performed in the present
study will be helpful in hypothesis testing and in discov-
ery, this model is not without caveats; measuring osteo-
porosis in mice will not accurately predict which bones
and bone regions will be most affected by hypercholes-
terolemia in humans because weight distribution in mice
is not the same.
In conclusion, a hypercholesterolemic non-athero-
genic diet contributes to development of an osteoporotic
bone phenotype in mice, including an increase in oste-
oclasts, loss of trabeculae, thinning of trabeculae and
cortex, and reductions in failure load and energy to
failure. This model of osteoporosis may provide an op-
portunity to critically evaluate various interventional strat-
egies to counteract the changes induced by a hypercho-
lesterolemic diet. Our data suggest that the correlation
between hypercholesterolemia and osteoporosis may be
a manifestation of failure to maintain cholesterol homeo-
stasis and an increase in osteoclast activity. Given the
increase in hyperlipidemia, metabolic syndrome, and
obesity in the United States and around the world, we
anticipate an increase in diet-induced osteoporosis, mak-
ing our novel model particularly timely.
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